Chronic Wounds
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Rochal IndustriesTX - San Antonio
1 programAtteris Antimicrobial Skin and Wound CleanserN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Carbon BiosciencesAmniotic Tissue Allograft
BioTherapeutics IncFGF-1
Rochal IndustriesAtteris Antimicrobial Skin and Wound Cleanser
Clinical Trials (3)
Total enrollment: 612 patients across 3 trials
Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
Start: Jan 2026Est. completion: Mar 2028600 patients
Phase 3Not Yet Recruiting
FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers
Start: Sep 2005Est. completion: Dec 20068 patients
Phase 1Completed
A Study to Investigate Two Atteris Antimicrobial Products on Chronic Wound Healing.
Start: Jul 2017Est. completion: Sep 20174 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.